Chikungunya
📧 Sign up to get email alerts when something new happens for Chikungunya.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-08-24EMA Authorised: Ixchiq (Chikungunya virus, strain CHIKV LR2006-OPY1, live attenuated) — Valneva Austria GmbH
EMA has authorized Ixchiq, a live attenuated chikungunya virus vaccine (strain CHIKV LR2006-OPY1) by Valneva Austria GmbH.
-
EMA approval · 2026-06-05EMA Authorised: Ixchiq (Chikungunya virus, strain CHIKV LR2006-OPY1, live attenuated) — Valneva Austria GmbH
EMA authorised Ixchiq (live attenuated chikungunya virus vaccine) for chikungunya virus indications.
-
CLINICAL_TRIALS trial_result · 2026-06-04Clinical Trial Results: A Multicenter Study to Evaluate Safety and Immunogenicity of a Live-attenuated Chikungunya Vaccine in Adolescents [Phase 3]
Phase 3 multicenter trial evaluating safety and immunogenicity of a live-attenuated chikungunya vaccine in adolescents has completed with re…
-
CLINICAL_TRIALS trial_result · 2026-06-04Clinical Trial Update: A Multicenter Study to Evaluate Safety and Immunogenicity of a Live-attenuated Chikungunya Vaccine in Adolescents [Phase 3]
Phase 3 multicenter study assessing safety and immunogenicity of a live-attenuated chikungunya vaccine in adolescents has completed; results…
-
CLINICAL_TRIALS trial_result · 2026-04-08Clinical Trial Update: Using Digital Technology for the Prevention of Aedes-Borne Diseases in Colombian Communities [NA]
Completed clinical trial in Colombia assessing digital technology for preventing dengue, Zika, and related Aedes-borne diseases.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-03-24Clinical Trial Update: A Safety and Immunogenicity Study of CHIKV VLP Vaccine in Children. [Phase 3]
An ongoing Phase 3 trial is evaluating the safety and immunogenicity of a chikungunya virus-like particle vaccine in children, sponsored by …
-
CLINICAL_TRIALS other · 2026-03-16Clinical Trial Update: An Efficacy, Safety, and Immunogenicity Study of CHIKV VLP Vaccine for the Prevention of Chikungunya Disease in Adolescents and Adults [Phase 3]
Clinical trial update for a CHIKV VLP vaccine to prevent chikungunya infection in adolescents and adults. The Phase 3 study is currently NOT…
-
EMA safety_alert · 2026-03-13Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 9 - 12 March 2026
PRAC warned of a known risk of aseptic meningitis with the chikungunya vaccine Ixchiq, prompting safety communications.
-
CLINICAL_TRIALS research · 2026-03-04Clinical Trial Update: Post-Chikungunya Rheumatism - Rheumatology Follow-up of Patients After 15 Years
This completed study follows patients who had chikungunya to assess long-term rheumatic symptoms 15 years after infection. It is sponsored b…
-
CLINICAL_TRIALS research · 2026-02-11Clinical Trial Update: Observational Study to Assess the Effectiveness of VLA1553 Vaccine in Preventing Chikungunya During a Pilot Vaccination Strategy in Brazil
An observational study is being conducted to assess the effectiveness of the VLA-1553 chikungunya vaccine in preventing chikungunya during a…
-
CLINICAL_TRIALS research · 2026-02-11Clinical Trial Update: Assessment of Chikungunya Virus Seroprevalence Before VLA1553 Vaccination in the Municipalities Selected for Participation in the VLA1553 Pilot Vaccination Strategy in Brazil
A Valneva-sponsored Brazil study is assessing baseline chikungunya virus seroprevalence in municipalities selected for the VLA1553 pilot vac…
-
CLINICAL_TRIALS research · 2026-02-06Clinical Trial Update: A Phase I Study of PepGNP-ChikV in Healthy Volunteers [EARLY_Phase 1]
Phase I study of PepGNP-ChikV in healthy volunteers is not yet recruiting, evaluating a chikungunya-targeted intervention.
-
CLINICAL_TRIALS research · 2026-01-22Clinical Trial Update: Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective
An ongoing recruitment update for a One Health study evaluating the risk of community spread of multiple endemic infectious diseases. The st…
-
CLINICAL_TRIALS research · 2025-12-11Clinical Trial Update: Methotrexate Treatment of Arthritis Caused by Chikungunya Virus (MARCH) [Phase 3]
Phase 3 trial evaluating methotrexate for arthritis caused by chikungunya virus. The study is currently active but not recruiting.
-
EMA approval · 2025-09-24EMA Authorised: Ixchiq (Chikungunya virus, strain CHIKV LR2006-OPY1, live attenuated) — Valneva Austria GmbH
The European Medicines Agency authorised Ixchiq, a live attenuated chikungunya virus vaccine (CHIKV LR2006-OPY1) developed by Valneva Austri…
-
CLINICAL_TRIALS trial_result · 2025-09-18Clinical Trial Update: Quantifying the Epidemiological Impact of Targeted Indoor Residual Spraying on Aedes-borne Diseases [NA]
Emory University completed a trial evaluating the epidemiological impact of targeted indoor residual spraying on Aedes-borne diseases. Resul…
-
EMA approval · 2025-08-22EMA Authorised: Vimkunya (Chikungunya virus (CHIKV) virus-like particle (VLP) proteins (capsid protein (C) and envelope proteins E1 and E2) derived from CHIKV Senegal strain 37997 produced in human embryonic kidney cells by recombinant DNA technology, adsorbed on aluminium hydroxide, hydrated) — Bavarian Nordic A/S
The EMA authorised Vimkunya for chikungunya. Vimkunya is a chikungunya virus-like particle vaccine produced in human embryonic kidney cells …
-
CLINICAL_TRIALS research · 2025-08-08Clinical Trial Update: Prospective Clinical Registry for Evaluation of Exanthematous Infections and Coinfections
A prospective clinical registry evaluating exanthematous infections and coinfections, including dengue fever, chikungunya, measles, and rube…
-
CLINICAL_TRIALS research · 2025-07-29Clinical Trial Update: Real-world Effectiveness, Safety and Immunogenicity of Chikungunya Vaccination in Populations at Risk of Severe or Complicated Forms: Prospective Study in La Réunion [Phase 4]
A Phase 4 prospective study in La Réunion to assess real-world effectiveness, safety, and immunogenicity of chikungunya vaccination in popul…
-
EMA safety_alert · 2025-07-25Ixchiq: temporary restriction on vaccinating people 65 years and older to be lifted
EMA says the temporary restriction on vaccinating people aged 65 and older with Ixchiq will be lifted. Vaccination should still be considere…
-
EMA safety_alert · 2025-07-11Ixchiq: temporary restriction on vaccinating people 65 years and older to be lifted
The European Medicines Agency has announced that the temporary restriction on vaccinating people aged 65 years and older with Ixchiq will be…
-
CLINICAL_TRIALS withdrawal · 2025-06-22Clinical Trial Update: Seamless Controlled Trial To Evaluate Safety And Immunogenicity of Chikungunya Vaccine in LatinAmerica and Asia [Phase 2, Phase 3]
A seamless Phase 2/3 trial evaluating the safety and immunogenicity of a chikungunya vaccine in Latin America and Asia has been terminated.
-
EMA safety_alert · 2025-05-07EMA starts review of Ixchiq (live attenuated chikungunya vaccine)
EMA has started a regulatory review of Ixchiq, a live attenuated chikungunya vaccine, and it should not be used in people aged 65 years and …
-
CLINICAL_TRIALS trial_result · 2025-02-11Clinical Trial Update: Impact of Differential and Systematic Diagnosis of Dengue, Chikungunya and Malaria on Patient Management and Antibiotic Use in West Africa [NA]
A completed trial evaluating how differential and systematic diagnosis of dengue, chikungunya, and malaria affects patient management and an…
-
EMA approval · 2025-01-31New Chikungunya vaccine for adolescents from 12 and adults
EMA approved Vimkunya, a chikungunya vaccine, for adolescents aged 12 years and older and adults; the review was expedited due to public hea…